amoxicillin

Amoxicillin is a semisynthetic beta-lactam antibiotic in the aminopenicillin subclass of the penicillin family. It is a medicine rather than a conventional consumer brand or operating company: the name is an international nonproprietary name used for products manufactured by many pharmaceutical companies. Its principal commercial identity comes from the generic active ingredient and from historical or regional brand names such as Amoxil. The medicine was developed from the 6-aminopenicillanic acid nucleus by scientists working for the Beecham Group in the United Kingdom. Amoxicillin was created as a successor to ampicillin, with substantially better absorption after oral administration. It entered medical use in 1972, and the Amoxil product received initial approval in the United States in 1974. The drug subsequently became a standard outpatient antibiotic in many markets and remains one of the most frequently prescribed antibacterial medicines, particularly for children. Amoxicillin works by binding to penicillin-binding proteins and disrupting the cross-linking of peptidoglycan in susceptible bacterial cell walls. This produces a bacteriolytic effect. Its activity covers a range of susceptible Gram-positive and Gram-negative organisms, although resistance is common in some bacterial species and varies by geography, organism, and clinical setting. Because it is vulnerable to beta-lactamase enzymes produced by some bacteria, it is often combined with clavulanic acid. The resulting medicine, commonly called co-amoxiclav or amoxicillin/clavulanate and historically marketed as Augmentin, has a broader antibacterial spectrum. Clinical uses include selected cases of acute otitis media, streptococcal pharyngitis, community-acquired pneumonia, bacterial sinusitis, urinary tract infection, skin and soft-tissue infection, dental or odontogenic infection, Lyme borreliosis, selected Salmonella and Chlamydia infections, and Helicobacter pylori eradication regimens when used with other medicines. It is also used in certain preventive settings, including selected dental procedures, prevention of infections in people without a functioning spleen, and anthrax prophylaxis or treatment. It is not effective against viral infections, and inappropriate use contributes to antimicrobial resistance. The medicine is available in multiple dosage forms, including capsules, conventional tablets, chewable tablets, dispersible tablets, oral powders and pediatric suspensions. Injectable sodium formulations are available in some countries, although the intravenous product is not marketed in the United States, where ampicillin is commonly used when an intravenous aminopenicillin is required. Dosing is adjusted according to indication, age, formulation, renal function, and local treatment guidance. Common adverse effects include nausea, vomiting, diarrhea, and skin rash. Hypersensitivity reactions can be serious or fatal, especially in people with a history of immediate allergy to penicillins or related beta-lactam antibiotics. A delayed, nonallergic maculopapular rash is relatively common in children and may occur during certain viral illnesses, particularly infectious mononucleosis. The amoxicillin/clavulanate combination is more strongly associated with diarrhea and can rarely cause drug-induced liver injury. Like other antibiotics, amoxicillin should be used only when a bacterial infection is proven or strongly suspected and according to professional prescribing guidance. Amoxicillin is included in the World Health Organization Model List of Essential Medicines and is categorized within the Access group of the WHO AWaRe antibiotic stewardship framework. Its importance derives from its low cost, oral absorption, pediatric utility, broad international availability, and established clinical evidence. At the same time, changing resistance patterns, shortages in some markets, and concerns about unnecessary prescribing have made stewardship, accurate diagnosis, and local susceptibility data central to its continued use. The underlying active ingredient is off patent and is manufactured by numerous generic suppliers worldwide.

Amoxicillin emerged from the postwar development of semisynthetic penicillins. The discovery of 6-aminopenicillanic acid made it possible for pharmaceutical researchers to preserve the penicillin core while attaching new chemical side chains intended to improve antibacterial coverage, pharmacokinetics, or tolerability. Beecham Research Laboratories in the United Kingdom became a major center of this work. Its scientists developed ampicillin, which entered clinical use in 1961, and then pursued related aminopenicillins with improved absorption after oral administration. Amoxicillin was discovered in 1958 and is generally attributed to Anthony Alfred Walter Long and John Herbert Charles Nayler, working within the Beecham research organization. Chemically, it is closely related to ampicillin but includes a hydroxyl group that improves oral absorption. This distinction helped make amoxicillin particularly useful in ambulatory medicine, where oral treatment is preferred over injection. It became available for medical use in 1972 and was the second major aminopenicillin to reach the market after ampicillin. Beecham commercialized the medicine under the Amoxil name. The United States approved Amoxil in 1974, while approval in the United Kingdom followed in 1977. Over time, the active ingredient spread through national health systems and generic markets. Its ability to be formulated as capsules, tablets, chewable tablets, dispersible tablets, and pediatric suspensions supported use across age groups and care settings. Pediatric liquid formulations became especially important because amoxicillin is commonly prescribed for childhood ear, throat, respiratory, and other bacterial infections. The history of amoxicillin is also closely linked to the development of beta-lactamase inhibitors. Many bacteria can produce beta-lactamase enzymes that inactivate penicillin-class antibiotics. Beecham researchers investigated clavulanic acid, a compound with weak antibacterial activity but strong beta-lactamase-inhibiting properties. Combining clavulanate with amoxicillin restored activity against some beta-lactamase-producing organisms and produced co-amoxiclav, marketed under names including Augmentin. The combination entered clinical practice in the United Kingdom in 1981 and in the United States in 1984. It became a major extension of the amoxicillin franchise, although it is pharmacologically and clinically distinct from amoxicillin alone. As patents expired and manufacturing expanded, amoxicillin became a widely available generic medicine. Its international nonproprietary name is used across markets, with the spelling amoxycillin retained in some historical or regional contexts. Numerous manufacturers now produce the ingredient and finished dosage forms, so there is no single contemporary owner or headquarters for the amoxicillin name. The historical Amoxil brand originated with Beecham; Beecham later became part of the corporate lineage that included SmithKline Beecham and ultimately GlaxoSmithKline, but generic amoxicillin is not controlled by that company. The medicine's clinical role has changed as bacterial resistance, diagnostic testing, and antibiotic-stewardship policies have developed. Amoxicillin remains a preferred treatment for several susceptible infections, including selected respiratory, ear, dental, skin, urinary, and gastrointestinal infections. It is also used in combination regimens for Helicobacter pylori and in selected prophylactic indications. However, it is ineffective against viral illnesses, and resistance limits its usefulness against some organisms, including many beta-lactamase-producing strains of Haemophilus influenzae, Moraxella catarrhalis, Escherichia coli, Klebsiella species, and Staphylococcus aureus. International public-health institutions continue to treat amoxicillin as an important access antibiotic. It appears on the WHO Model List of Essential Medicines and in pediatric essential-medicines guidance. The WHO AWaRe framework places emphasis on preserving the effectiveness of antibiotics through appropriate selection and use. Recent reviews have narrowed some empiric indications, including the removal of amoxicillin as an empiric option for lower urinary tract infection in the 2021 Model List review. This illustrates the drug's continuing importance but also the need for recommendations to evolve with resistance patterns. By the 2020s, amoxicillin remained one of the most commonly prescribed antibiotics in the United States and many other countries. Its continuing relevance rests on a combination of clinical familiarity, oral bioavailability, pediatric formulations, low manufacturing cost, and extensive experience in ordinary outpatient care. Its principal challenges are antimicrobial resistance, inappropriate prescribing, supply interruptions, allergy labeling, adverse effects, and the need to distinguish bacterial disease from viral infection.

• 2025

  Amoxicillin retained in updated WHO essential-medicines framework

  [5]The selection and use of essential medicines: 2025 WHO Model Listwho.int

  The WHO published its 24th Model List of Essential Medicines and related antibiotic-stewardship materials, continuing the global essential-medicine framework in which amoxicillin is used.

• 2023

  Amoxicillin remains among the most prescribed United States medicines

  [11]Amoxicillin Drug Usage Statisticsclincalc.com

  Prescription estimates for 2023 placed amoxicillin at approximately 23.5 million prescriptions and number 23 among all medicines in the cited United States dataset.

• 2021

  WHO narrows empiric urinary-tract-infection guidance

  [7]WHO 23rd Expert Committee on Selection and Use of Essential Medicineswho.int

  The WHO Expert Committee recommended removing amoxicillin as an empiric option for lower urinary tract infections from the Model Lists.

• 2017

  WHO highlights amoxicillin within essential antibiotic policy

  [12]WHO highlights amoxicillin within essential antibiotic policywho.int

  The WHO continued to identify amoxicillin as a widely used antibiotic and included it within updated essential-medicines and antibiotic-use guidance.

• 1984

  United States introduction of amoxicillin/clavulanate

  [8]Three Decades of Beta-Lactamase Inhibitorspmc.ncbi.nlm.nih.gov

  The amoxicillin-clavulanate combination entered clinical practice in the United States.

• 1981

  Co-amoxiclav enters clinical practice

  [8]Three Decades of Beta-Lactamase Inhibitorspmc.ncbi.nlm.nih.gov

  Amoxicillin/clavulanate was introduced in the United Kingdom as an oral beta-lactam/beta-lactamase-inhibitor combination, extending the commercial and clinical role of amoxicillin.

• 1977

  United Kingdom approval

  [1]Amoxicillinen.wikipedia.org

  Amoxicillin received medical approval in the United Kingdom.

• 1974

  Initial United States approval of Amoxil

  [4]Amoxil FDA labelingaccessdata.fda.gov

  The FDA label records 1974 as the initial United States approval year for Amoxil amoxicillin products.

• 1972

  Amoxicillin enters medical use

  [1]Amoxicillinen.wikipedia.org

  Amoxicillin became available for medical use and was commercialized by Beecham as Amoxil.

• 1959

  Publication of foundational Beecham penicillin research

  [9]Synthesis of Penicillin: 6-Aminopenicillanic Acid in Penicillin Fermentationsnature.com

  Beecham scientists published important work on the synthesis and industrial development of 6-aminopenicillanic acid, the core used to make later semisynthetic penicillins.

• 1958

  Discovery of amoxicillin

  [1]Amoxicillinen.wikipedia.org

  Amoxicillin was discovered during Beecham's program to develop semisynthetic derivatives of the penicillin nucleus.

A widely available, relatively inexpensive, first-line or preferred oral aminopenicillin for susceptible bacterial infections, with strong pediatric and primary-care relevance. Its positioning is based on established efficacy, oral absorption, global generic availability, and inclusion on essential-medicines lists rather than on a single corporate brand owner.

• Prescription antibiotic · 1972

  Generic oral amoxicillin capsules

  Capsules containing amoxicillin trihydrate are among the most common adult dosage forms. They are used for susceptible bacterial infections across respiratory, ear, dental, skin, urinary, and other clinical indications. Strengths and dosing schedules vary by market and indication. Generic capsule products are manufactured by many pharmaceutical companies and are not controlled by a single brand owner.

• Prescription antibiotic · 1972

  Generic oral amoxicillin tablets

  Immediate-release tablets provide an alternative to capsules for patients who can swallow solid dosage forms. They contain amoxicillin trihydrate and are used according to infection type, patient age, renal function, and local prescribing guidance. Tablet formulations support large-scale outpatient dispensing and are widely available as low-cost generics.

• Pediatric and oral antibiotic formulation

  Chewable and dispersible amoxicillin tablets

  Chewable and dispersible forms are designed to improve administration for children or adults who have difficulty swallowing conventional tablets. These formulations expand access to weight-adjusted oral therapy and are included in national and international pediatric medicine supply programs in some markets.

• Pediatric antibiotic formulation · 1972

  Amoxicillin oral suspension

  Powder for reconstitution into an oral suspension is a major pediatric form of amoxicillin. It allows dosing by body weight and is commonly used for childhood ear, throat, respiratory, and other susceptible bacterial infections. Storage requirements, concentration, reconstitution instructions, and stability after mixing differ by product.

• Parenteral antibiotic

  Amoxicillin sodium injection

  Amoxicillin sodium is an injectable formulation used in some countries when parenteral aminopenicillin therapy is required. It may be supplied as powder for intravenous or intramuscular administration. Availability is market-specific; an intravenous amoxicillin product is not marketed in the United States, where ampicillin is commonly used for comparable intravenous aminopenicillin treatment.

• Historical branded amoxicillin · 1972

  Amoxil

  Amoxil is the principal historical brand associated with amoxicillin. It was developed and launched by Beecham and received initial United States approval in 1974. Depending on market and product presentation, the name has been used for capsules, tablets, chewable tablets, and oral suspension. The underlying amoxicillin molecule is now widely available from generic manufacturers.

• Beta-lactam/beta-lactamase-inhibitor combination · 1981

  Amoxicillin/clavulanate

  Amoxicillin/clavulanate combines amoxicillin with clavulanic acid, which inhibits several beta-lactamase enzymes and expands activity against selected resistant bacteria. It is commonly known as co-amoxiclav and has been marketed under names including Augmentin. It is a related combination product rather than amoxicillin alone and has a different adverse-effect profile, particularly a higher frequency of diarrhea.

• 2025

  Continuation within the WHO essential-medicines frameworkStrategy

  Background

  The WHO updates its Model List of Essential Medicines and antibiotic stewardship framework on a regular cycle.

  Action taken

  The WHO published its 24th Model List and updated AWaRe materials, maintaining the global policy framework supporting access to appropriately used antibiotics such as amoxicillin.

  Aftermath

  Amoxicillin continued to be treated as a globally important access medicine, subject to stewardship and resistance-aware prescribing.

  Source

• 2021

  WHO narrows empiric lower urinary tract infection useStrategy

  Background

  The WHO reviewed medicines on its Model Lists in light of contemporary evidence, resistance patterns, and appropriate antibiotic use.

  Action taken

  The Expert Committee recommended removing amoxicillin as an empiric option for lower urinary tract infections from the Model Lists.

  Aftermath

  Amoxicillin remained an essential medicine for other indications, while its empiric use for urinary infections became more restricted in WHO guidance.

  Source

• 1981

  Introduction of amoxicillin/clavulanateProduct launch

  Background

  Beta-lactamase-producing bacteria reduced the effectiveness of amoxicillin and other penicillin-class antibiotics.

  Action taken

  Beecham introduced the oral amoxicillin/clavulanate combination, adding clavulanic acid as a beta-lactamase inhibitor.

  Aftermath

  The combination broadened activity against selected resistant organisms and became a major related product under the Augmentin name.

  Source

• 1974

  Initial United States regulatory approvalOther

  Background

  The FDA evaluated Amoxil as a penicillin-class antibacterial for infections caused by susceptible organisms.

  Action taken

  The United States granted initial approval for Amoxil capsules, tablets, and powder for oral suspension.

  Aftermath

  United States prescribing and subsequent generic competition established amoxicillin as a mainstream oral antibiotic.

  Source

• 1972

  Launch of amoxicillin and AmoxilProduct launch

  Background

  Beecham developed amoxicillin as an orally better-absorbed semisynthetic aminopenicillin related to ampicillin.

  Action taken

  The company introduced amoxicillin into medical use and commercialized it under the Amoxil name.

  Aftermath

  The medicine became a major outpatient antibiotic and later expanded through generic manufacturing and multiple oral dosage forms.

  Source

• 2025

  WHO publishes updated essential-medicines and antibiotic-stewardship lists[5]The selection and use of essential medicines: 2025 WHO Model Listwho.int

  Regulation

  The World Health Organization published its 24th Model List of Essential Medicines and updated AWaRe antibiotic classification in September 2025. Amoxicillin remains part of the essential-medicines and Access-antibiotic framework.

• 2023

  Amoxicillin remains a high-volume antibiotic in United States outpatient prescribing[11]Amoxicillin Drug Usage Statisticsclincalc.com

  Other

  United States prescription estimates placed amoxicillin among the country's most frequently prescribed medicines in 2023, with approximately 23.5 million prescriptions and a rank of number 23 across all medicines in the cited dataset.

• 2023

  CDC reports amoxicillin as the leading oral antibiotic agent in United States prescribing[10]CDC Outpatient Antibiotic Prescriptions 2023 Reportcdc.gov

  Other

  The CDC's 2023 outpatient antibiotic report identified amoxicillin as the most frequently prescribed individual oral antibiotic agent in the United States, with an estimated 57.1 million prescriptions.

• 2021

  WHO reviews the role of amoxicillin in empiric lower urinary tract infection treatment[7]WHO 23rd Expert Committee on Selection and Use of Essential Medicineswho.int

  Regulation · Other

  The WHO Expert Committee recommended removing amoxicillin as an empiric option for lower urinary tract infections from the Model Lists, reflecting concerns about resistance and the need to align empiric therapy with current evidence.

• 1974

  Amoxil receives initial United States approval[4]Amoxil FDA labelingaccessdata.fda.gov

  Product launch

  The FDA labeling history for Amoxil records an initial United States approval in 1974 for amoxicillin capsules, tablets, and oral suspension products.

1. 1Amoxicillinen.wikipedia.org
2. 2AMOXICILLIN capsule — DailyMeddailymed.nlm.nih.gov
3. 3Amoxicillin — Oral Productsfda.gov
4. 4Amoxil FDA labelingaccessdata.fda.gov
5. 5The selection and use of essential medicines: 2025 WHO Model Listwho.int
6. 6WHO AWaRe classification of antibioticswho.int
7. 7WHO 23rd Expert Committee on Selection and Use of Essential Medicineswho.int
8. 8Three Decades of Beta-Lactamase Inhibitorspmc.ncbi.nlm.nih.gov
9. 9Synthesis of Penicillin: 6-Aminopenicillanic Acid in Penicillin Fermentationsnature.com
10. 10CDC Outpatient Antibiotic Prescriptions 2023 Reportcdc.gov
11. 11Amoxicillin Drug Usage Statisticsclincalc.com
12. 12WHO highlights amoxicillin within essential antibiotic policywho.int